Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada(Shizuoka Cancer Center), Tetsuya Nakatsura(National Cancer Center Hospital East), Toshimitsu Kuronuma(Shizuoka Cancer Center), Shoichi Mizuno(Shizuoka Cancer Center), Kohei Nakachi(National Cancer Center Hospital East), Toshiaki Yoshikawa(Aichi Cancer Center), Naoto Gotohda(Shizuoka Cancer Center), Daisuke Nobuoka(Shizuoka Cancer Center), Junji Furuse(Kyorin University), Hiroshi Ishii(Chiba Cancer Center), Masaru Konishi(Shizuoka Cancer Center), Kenji Yamao(National Cancer Center Hospital East), Toshio Nakagohri(Tokai University), Shinichiro Takahashi(Shizuoka Cancer Center), Tadatoshi Takayama(Nihon University), Hirofumi Shirakawa(Shizuoka Cancer Center), Yutaka Motomura(Shizuoka Cancer Center), Taira Kinoshitá(National Cancer Center Hospital East), Katsuhiko Uesaka(Shizuoka Cancer Center)
Cited by 299
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749